Evaluate the Knowledge and Understanding of Anesthesiologists Use of BRIDION® solution for injection, 100 mg/mL sugammadex (as sugammadex sodium) in Canada

Study type

• Study topic:
  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Other
• If ‘other’, further details on the scope of the study:
  Knowledge and Understanding (KAU) Survey
• Data collection methods:
  Primary data collection

Non-interventional study

• Non-interventional study design:
  Cross-sectional

  Other
• Non-interventional study design, other:
  Observational survey

Study drug and medical condition

• Medicinal product name, other:
  BRIDIONTM

Population studied

• Short description of the study population:
  Anesthesiologists who have participated in Merck-sponsored educational programs related to BRIDION™ and anesthesiologists who have administered BRIDION™ in the past 12 months will also be included.; ; Participants must be anesthesiologists who meet at least one of the inclusion criteria below:; • Have been identified by Merck as having previously participated in Merck-sponsored educational programs related to BRIDION™.; • Have administered BRIDION™ in the past 12 months. ; ; Prospective participants will not be accepted if they meet at least one of the exclusion criteria below:; • Have immediate family members who have ever worked for Merck Canada Inc., or any of its affiliates, or UBC.; • Do not fulfil either of the inclusion criteria.
• Age groups:
  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)
• Estimated number of subjects:
  200

Study design details

• Main study objective:
  To assess how anesthesiologists use BRIDIONTM and to evaluate how well anesthesiologists understand the safety and efficacy aspects of BRIDIONTM.
• Data analysis plan:
  Data collected from the survey will be reported as descriptive statistics. Responses to each question relating to the knowledge and understanding of the use, safety and efficacy aspects, of BRIDIONTM, will be categorized as a “correct response” or an “incorrect response." Frequency distributions with exact binomial two-sided 95% confidence intervals (CIs) will be calculated for responses to questions that address the survey objectives.